



Living with **ocular (eye-only) myasthenia gravis?**

We seek the support of people living with **ocular (eye-only) symptoms of myasthenia gravis** for the **MyVision study**. If you or someone you know lives with ocular myasthenia gravis (oMG), we would like to hear from you.

MyVision 

Welcome!

The MyVision study is testing a study drug to see the effects on eye-only symptoms in adults with ocular myasthenia gravis (oMG).

The MyVision study is hoping to better understand oMG and its symptoms while advancing scientific research at the same time. The aim of the study is to learn how well the study drug works (efficacy) and what side effects people experience while taking it (safety).

To be eligible to join the study, participants must:



Be at least **18** years of age



Have been **diagnosed with oMG** by a doctor



Not be experiencing weakness in other muscles in the body such as the face, throat, arms, and/or legs

There are other requirements for taking part in this study, which the study team will discuss with you.

There is also an extension study that participants may be eligible to join called MyVisionXT where participants can keep receiving the study drug for an extended period of time.

But first ... A Word of Thanks!

Thank you for your interest in the MyVision study.

We know that living or supporting someone with ocular (eye-only) myasthenia gravis (oMG) can be unpredictable and challenging and varies from day to day.

We understand that oMG can cause double vision, droopy eyelids, fatigue, light sensitivity, and difficulty looking in different directions. From discussions we've had with patients, we recognize that these symptoms can make driving, reading, and watching television challenging, even if you are already on treatment.

The decision to take part in a clinical research study may seem overwhelming, so we encourage you to discuss the MyVision study with your family, friends, and the study team before making the decision to join.

If you or someone you know is interested in joining the MyVision study, the study team will share detailed information about the study with you. This includes what the study involves, what to expect, and how the study team will support you. They are available to answer questions and address any concerns that you or your loved one(s) may have, so you can make a decision that feels right for you.

If you have any questions about the study or would like more information on how to join, please contact the study team (see contact details on the back) or visit our website at myvisionstudy.com.



About Clinical Research

The MyVision study is a clinical research study, also known as a clinical trial. Clinical research is needed to decide whether a study drug should become available to the public to treat a specific condition.

During a clinical study, researchers may want to find out the following about a study drug:

- If it has manageable side effects
- If it works the way it is expected to
- If it works less well, the same, or better than other drugs
- How it behaves in the human body (eg, where it is transported, how quickly it leaves the body, etc.)

Before any medication can be prescribed or made available to the public, it must go through clinical studies and then be approved by regulatory health organizations. These studies follow strict rules to protect the rights, safety, well-being, and privacy of participants, while providing the information health officials need to decide whether a medication is tolerated well and is effective. Clinical studies are the only way new treatments can be developed.

Why We're Doing This Study

The aim of the study is to learn how well the study drug works (efficacy) and what side effects people experience while taking it (safety).

By testing a study drug (this means a drug that is not yet approved for the treatment of oMG), like the one in the MyVision study, researchers hope to find out if it could also help reduce symptoms of oMG. This could possibly help others like you in the future.

What Is the MyVision Study Testing?

The MyVision study is testing a study drug currently approved for the treatment of generalized myasthenia gravis (gMG) but not ocular myasthenia gravis. In the MyVision study, researchers want to find out if it could also help reduce symptoms of oMG.

Unlike other treatments such as corticosteroids or immune globulin infusions, the study drug takes a different approach. It works by affecting the part of the immune system that can cause problems where nerves connect to muscles—which is what leads to oMG.

What Does Study Participation Involve?

- The study lasts up to 19 weeks with 13 study visits.
- There is a 50% chance of receiving the study drug and a 50% chance of receiving placebo. A placebo looks like the real medicine but does not contain any medicinally active ingredients.
- Both the study drug and the placebo will be given under the skin (injected subcutaneously, also known as an SC injection) once a week for 6 weeks.
- The study is double-blinded. This means that neither you nor the study team will know or be able to decide whether the participant will receive the study drug or a placebo.
- After you sign an Informed Consent Form or ICF (an ICF explains risks, benefits, and what to expect), you begin screening (screening is a series of assessments to see if the study is right for you).
- After confirming you meet all the study criteria to participate and you agree in writing to join the study, you are then randomly assigned (like flipping a coin) to receive either the study drug or a placebo (a look-alike with no active medicine).
- With few exceptions, you will be able to remain on your current medications for your eyes, but the dose and frequency must remain unchanged for a 6-week treatment period, which will be explained in more detail by the study team.

What Are the Potential Risks and Benefits of the Study?

The MyVision study is being done to learn more about the study drug. Because this drug is still being researched, there is no guarantee that taking part will help you.

All medicines can cause side effects. One of the main goals of this study is to watch for side effects in people who take the study drug. Before you decide to join, you will get detailed information about the side effects that have already been seen in earlier studies with this study drug. If you have any concerns or questions about possible side effects, please talk to the study team—they are here to help you.

Additional Treatment During the MyVision study

Your study doctor may ask you to take additional medication to improve your oMG symptoms if they worsen while you are on the study drug. These medications may be adjustments of the medications that you were on when you entered the study or other medications sometimes used to treat worsening symptoms of oMG.

What is MyVisionXT?

At the end of the MyVision study (if you are still eligible), you will have the opportunity to enter MyVisionXT, which is a 2-year open-label extension (OLE) study. Open-label means that all study participants will receive the study drug—there is no chance of a placebo being given (like there was in the MyVision study). The goal of this study is to help researchers understand which side effects may occur when the study drug is used for a longer period of time.

Please discuss your options with the study team, including how you might continue in the MyVisionXT study.

How Long Will Study Participation Last?

The MyVision study lasts up to 19 weeks in total, with up to 13 visits to the study center. The study has the following 4 periods:

- **Screening period:** Up to 6 weeks
- **Treatment period:** 6 weeks (weekly doses of study drug or placebo)
- **Observation period:** 4 to 7 weeks, depending on whether you choose to enter the MyVisionXT extension study or not

Below is an illustration of how the MyVision study plays out:



The study team and the informed consent form will tell you more about the study. If at any time you have concerns about how long a study visit may take or about comfort during a visit, please raise this to a member of the study team.

Deciding to Join the MyVision study

Participation in the MyVision study is completely up to you. If you join, you can decide to leave the study at any time without giving a reason. Deciding not to take part or leaving the study early will not affect your medical care now or in the future.

The MyVision study team developed all study materials in close partnership with the oMG community, ensuring their voices and unique needs were heard from the outset. We understand the specific challenges faced by people living with ocular (eye-only) myasthenia gravis (oMG), and have prioritized comfort, accessibility, and clear communication throughout.

We want to make your study participation as easy and stress-free as possible. Comprehensive travel reimbursement support and compensation may be provided. Your safety, well-being, and convenience are central to our approach. We appreciate your interest in the study as the most important people in clinical research are study volunteers. Without people like you, clinical studies could not take place.

Please reach out to the study team with any concerns, as we are committed to making your study experience as accommodating as possible.



We would like to thank you for considering taking part in the MyVision study. If you have any questions about the study or how to join, please contact the study team or visit our website at myvisionstudy.com.



The MyVision study is sponsored by UCB, a global biopharma company based in Belgium that is focusing on neurology and immunology disorders, including a number of different autoimmune diseases.

